NCT00534391

Brief Summary

To compare the effectiveness of combined antibiotic ophthalmic solution (neomycin sulfate, polymyxin B sulfate and gramicidin) with placebo (artificial tear) in the treatment of hordeolum after incision and curettage

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
120

participants targeted

Target at P25-P50 for phase_3

Timeline
Completed

Started Sep 2007

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

September 1, 2007

Completed
20 days until next milestone

First Submitted

Initial submission to the registry

September 21, 2007

Completed
3 days until next milestone

First Posted

Study publicly available on registry

September 24, 2007

Completed
1.2 years until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2008

Completed
Last Updated

November 23, 2010

Status Verified

November 1, 2010

First QC Date

September 21, 2007

Last Update Submit

November 22, 2010

Conditions

Keywords

Antibioticshordeolum

Outcome Measures

Primary Outcomes (1)

  • Pain scale

    1,3,7 days after treatment

Secondary Outcomes (1)

  • Mass size and duration of cure

    1, 3, 7, 30 days after treatment

Study Arms (2)

B

PLACEBO COMPARATOR

Artificial tear containing antibiotic solution base

Drug: Artificial tear

A

EXPERIMENTAL

combined antibiotic ophthalmic solution (neomycin sulfate, polymyxin B sulfate and gramicidin)

Drug: neomycin sulfate, polymyxin B sulfate and gramicidin

Interventions

to the effected eye 4 times a day

Also known as: Neosporin, Polyoph
A

4 times daily

Also known as: Tear natural II, Lacoph
B

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • at least 5-millimeters hordeolum
  • the onset within 7 days

You may not qualify if:

  • previous incision and curettage of the same site within 1 month or more than 3 times
  • lesions in the adjacent areas suggesting of complications associated with hordeolum such as preseptal cellulitis or blepharitis
  • The patients with immunodeficiency, history of bleeding tendency
  • allergy to aminoglycoside, polymyxin B, gramicidin, xylocaine and povidone iodine

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Ophthalmology, Chulalongkorn University

Bangkok, 10330, Thailand

RECRUITING

Related Publications (1)

  • Hirunwiwatkul P, Wachirasereechai K. Effectiveness of combined antibiotic ophthalmic solution in the treatment of hordeolum after incision and curettage: a randomized, placebo-controlled trial: a pilot study. J Med Assoc Thai. 2005 May;88(5):647-50.

    PMID: 16149682BACKGROUND

MeSH Terms

Conditions

Hordeolum

Interventions

NeomycinPolymyxin BGramicidinbacitracin zinc, neomycin sulfate, polymyxin B, drug combinationLubricant Eye Drops

Condition Hierarchy (Ancestors)

Eye Infections, BacterialBacterial InfectionsBacterial Infections and MycosesInfectionsEye InfectionsEye DiseasesEyelid Diseases

Intervention Hierarchy (Ancestors)

AminoglycosidesGlycosidesCarbohydratesPolymyxinsPeptides, CyclicMacrocyclic CompoundsPolycyclic CompoundsLipopeptidesLipidsAntimicrobial Cationic PeptidesPeptidesAmino Acids, Peptides, and ProteinsAntimicrobial PeptidesPore Forming Cytotoxic ProteinsMembrane ProteinsProteinsTyrothricinOphthalmic SolutionsPharmaceutical SolutionsSolutionsPharmaceutical PreparationsTherapeutic UsesPharmacologic ActionsChemical Actions and UsesLubricantsSpecialty Uses of Chemicals

Study Officials

  • Parima Hirunwiwatkul, MD

    Department of Ophthalmology, Faculty of Medicine, Chulalongkorn University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Parima Hirunwiwatkul, MD

CONTACT

Puangphet Chalermphanich, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

September 21, 2007

First Posted

September 24, 2007

Study Start

September 1, 2007

Study Completion

December 1, 2008

Last Updated

November 23, 2010

Record last verified: 2010-11

Locations